These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21337314)

  • 1. Combined evaluation of matrix metalloproteinases and their inhibitors has better clinical utility in oral cancer.
    Singh RD; Nilayangode H; Patel JB; Shah FD; Shukla SN; Shah PM; Patel PS
    Int J Biol Markers; 2011; 26(1):27-36. PubMed ID: 21337314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Plasma Matrix Metalloproteinase and Tissue Inhibitors of Matrix Metalloproteinase Levels With Adverse Treatment Outcomes Among Patients With Pulmonary Tuberculosis.
    Kumar NP; Moideen K; Nancy A; Viswanathan V; Thiruvengadam K; Sivakumar S; Hissar S; Nair D; Banurekha VV; Kornfeld H; Babu S
    JAMA Netw Open; 2020 Dec; 3(12):e2027754. PubMed ID: 33258908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of MMPS, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis.
    Kurahara S; Shinohara M; Ikebe T; Nakamura S; Beppu M; Hiraki A; Takeuchi H; Shirasuna K
    Head Neck; 1999 Oct; 21(7):627-38. PubMed ID: 10487950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
    Lorenzl S; Buerger K; Hampel H; Beal MF
    Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
    Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis.
    Sutinen M; Kainulainen T; Hurskainen T; Vesterlund E; Alexander JP; Overall CM; Sorsa T; Salo T
    Br J Cancer; 1998 Jun; 77(12):2239-45. PubMed ID: 9649139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, aminoterminal propeptide of procollagen type III, and hyaluronan in sera and tissue of patients with capsular contracture after augmentation with Trilucent breast implants.
    Ulrich D; Lichtenegger F; Eblenkamp M; Repper D; Pallua N
    Plast Reconstr Surg; 2004 Jul; 114(1):229-36. PubMed ID: 15220598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor progression driven by pathways activating matrix metalloproteinases and their inhibitors.
    Bodnar M; Szylberg Ł; Kazmierczak W; Marszalek A
    J Oral Pathol Med; 2015 Jul; 44(6):437-43. PubMed ID: 25244188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with moderate and severe traumatic brain injury.
    Zheng K; Li C; Shan X; Liu H; Fan W; Wang Z; Zheng P
    Neurol India; 2013; 61(6):606-9. PubMed ID: 24441327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis.
    Mühl D; Nagy B; Woth G; Falusi B; Bogár L; Weber G; Lantos J
    J Crit Care; 2011 Dec; 26(6):550-5. PubMed ID: 21530151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients.
    Giannelli G; Erriquez R; Fransvea E; Daniele A; Trerotoli P; Schittulli F; Grano M; Quaranta M; Antonaci S
    Int J Cancer; 2004 May; 109(5):782-5. PubMed ID: 14999790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive Value of Matrix Metalloproteinases and Their Inhibitors for Mortality in Septic Patients: A Cohort Study.
    Serrano-Gomez S; Burgos-Angulo G; Niño-Vargas DC; Niño ME; Cárdenas ME; Chacón-Valenzuela E; McCosham DM; Peinado-Acevedo JS; Lopez MM; Cunha F; Pazin-Filho A; Ilarraza R; Schulz R; Torres-Dueñas D
    J Intensive Care Med; 2020 Jan; 35(1):95-103. PubMed ID: 28931365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of vascular endothelial growth factor, metalloproteinases and their tissue inhibitors with cardiovascular risk factors in the metabolic syndrome.
    Erman H; Gelisgen R; Cengiz M; Tabak O; Erdenen F; Uzun H
    Eur Rev Med Pharmacol Sci; 2016; 20(6):1015-22. PubMed ID: 27049251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure.
    Wilson EM; Gunasinghe HR; Coker ML; Sprunger P; Lee-Jackson D; Bozkurt B; Deswal A; Mann DL; Spinale FG
    J Card Fail; 2002 Dec; 8(6):390-8. PubMed ID: 12528092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effects of MMPs and TIMPs on the metastasis of oral squamous cell carcinoma to neck lymph nodes].
    Liu G; Li J; Li Z; Chen X
    Hua Xi Kou Qiang Yi Xue Za Zhi; 2001 Aug; 19(4):216-8, 224. PubMed ID: 12539723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Serum interleukin 6 (il-6A) concentration correlates with matrix metalloproteinases and their tissue inhibitors in rheumatoid arthritis].
    Klimiuk PA; Sierakowski S; Chwiećko J
    Pol Arch Med Wewn; 2003 Feb; 109(2):119-23. PubMed ID: 12879774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of matrix metalloproteinases and their tissue inhibitors in inflammatory bowel diseases.
    Lakatos G; Hritz I; Varga MZ; Juhász M; Miheller P; Cierny G; Tulassay Z; Herszényi L
    Dig Dis; 2012; 30(3):289-95. PubMed ID: 22722554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of serum matrix metalloproteinases as biomarkers for detection of neurological symptoms in carotid artery disease.
    Heider P; Pelisek J; Poppert H; Eckstein HH
    Vasc Endovascular Surg; 2009 Dec; 43(6):551-60. PubMed ID: 19640916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver Fibrosis in HCV Monoinfected and HIV/HCV Coinfected Patients: Dysregulation of Matrix Metalloproteinases (MMPs) and Their Tissue Inhibitors TIMPs and Effect of HCV Protease Inhibitors.
    Latronico T; Mascia C; Pati I; Zuccala P; Mengoni F; Marocco R; Tieghi T; Belvisi V; Lichtner M; Vullo V; Mastroianni CM; Liuzzi GM
    Int J Mol Sci; 2016 Mar; 17(4):455. PubMed ID: 27023536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases Are Potential Biomarkers of Pulmonary and Extra-Pulmonary Tuberculosis.
    Kathamuthu GR; Kumar NP; Moideen K; Nair D; Banurekha VV; Sridhar R; Baskaran D; Babu S
    Front Immunol; 2020; 11():419. PubMed ID: 32218787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.